ATXS
Price
$4.04
Change
+$0.06 (+1.51%)
Updated
Apr 17 closing price
Capitalization
227.99M
19 days until earnings call
ZIVO
Price
$16.00
Change
+$1.01 (+6.74%)
Updated
Apr 17 closing price
Capitalization
60.15M
Ad is loading...

ATXS vs ZIVO

Header iconATXS vs ZIVO Comparison
Open Charts ATXS vs ZIVOBanner chart's image
Astria Therapeutics
Price$4.04
Change+$0.06 (+1.51%)
Volume$202.27K
Capitalization227.99M
Zivo Bioscience
Price$16.00
Change+$1.01 (+6.74%)
Volume$1.7K
Capitalization60.15M
ATXS vs ZIVO Comparison Chart
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. ZIVO commentary
Apr 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Hold and ZIVO is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 19, 2025
Stock price -- (ATXS: $4.04 vs. ZIVO: $16.00)
Brand notoriety: ATXS and ZIVO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 68% vs. ZIVO: 251%
Market capitalization -- ATXS: $227.99M vs. ZIVO: $60.15M
ATXS [@Biotechnology] is valued at $227.99M. ZIVO’s [@Biotechnology] market capitalization is $60.15M. The market cap for tickers in the [@Biotechnology] industry ranges from $282.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileZIVO’s FA Score has 0 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • ZIVO’s FA Score: 0 green, 5 red.
According to our system of comparison, ZIVO is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 4 TA indicator(s) are bullish.

  • ATXS’s TA Score: 4 bullish, 4 bearish.

Price Growth

ATXS (@Biotechnology) experienced а -0.49% price change this week, while ZIVO (@Biotechnology) price change was -5.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.03%. For the same industry, the average monthly price growth was -13.25%, and the average quarterly price growth was -24.49%.

Reported Earning Dates

ATXS is expected to report earnings on Aug 11, 2025.

ZIVO is expected to report earnings on Feb 28, 2024.

Industries' Descriptions

@Biotechnology (+7.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATXS($228M) has a higher market cap than ZIVO($60.1M). ZIVO YTD gains are higher at: -25.581 vs. ATXS (-54.810). ZIVO has higher annual earnings (EBITDA): -13.36M vs. ATXS (-111.56M). ATXS has more cash in the bank: 328M vs. ZIVO (1.54M). ZIVO has less debt than ATXS: ZIVO (254K) vs ATXS (5.35M). ZIVO has higher revenues than ATXS: ZIVO (157K) vs ATXS (0).
ATXSZIVOATXS / ZIVO
Capitalization228M60.1M379%
EBITDA-111.56M-13.36M835%
Gain YTD-54.810-25.581214%
P/E RatioN/AN/A-
Revenue0157K-
Total Cash328M1.54M21,271%
Total Debt5.35M254K2,107%
FUNDAMENTALS RATINGS
ATXS vs ZIVO: Fundamental Ratings
ATXS
ZIVO
OUTLOOK RATING
1..100
7750
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
83
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
9646
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXS's Valuation (62) in the Biotechnology industry is in the same range as ZIVO (83) in the null industry. This means that ATXS’s stock grew similarly to ZIVO’s over the last 12 months.

ATXS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ZIVO (100) in the null industry. This means that ATXS’s stock grew similarly to ZIVO’s over the last 12 months.

ATXS's SMR Rating (97) in the Biotechnology industry is in the same range as ZIVO (100) in the null industry. This means that ATXS’s stock grew similarly to ZIVO’s over the last 12 months.

ZIVO's Price Growth Rating (46) in the null industry is somewhat better than the same rating for ATXS (96) in the Biotechnology industry. This means that ZIVO’s stock grew somewhat faster than ATXS’s over the last 12 months.

ZIVO's P/E Growth Rating (100) in the null industry is in the same range as ATXS (100) in the Biotechnology industry. This means that ZIVO’s stock grew similarly to ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXS
RSI
ODDS (%)
Bullish Trend 3 days ago
72%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
79%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
89%
Advances
ODDS (%)
Bullish Trend 30 days ago
82%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
74%
Aroon
ODDS (%)
Bearish Trend 3 days ago
87%
View a ticker or compare two or three
Ad is loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME26.780.53
+2.02%
GameStop Corp
AAPL196.982.71
+1.39%
Apple
SPY526.410.75
+0.14%
SPDR® S&P 500® ETF
TSLA241.37-0.18
-0.07%
Tesla
BTC.X84450.805000-444.945300
-0.52%
Bitcoin cryptocurrency

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with TRDA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+1.51%
TRDA - ATXS
52%
Loosely correlated
+3.44%
KYMR - ATXS
52%
Loosely correlated
+3.80%
XENE - ATXS
50%
Loosely correlated
+3.94%
DNLI - ATXS
49%
Loosely correlated
+1.51%
IMNM - ATXS
49%
Loosely correlated
+10.32%
More

ZIVO and

Correlation & Price change

A.I.dvisor tells us that ZIVO and MDXXF have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ZIVO and MDXXF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZIVO
1D Price
Change %
ZIVO100%
+6.74%
MDXXF - ZIVO
22%
Poorly correlated
+14.31%
ATXS - ZIVO
21%
Poorly correlated
+1.51%
ETXPF - ZIVO
21%
Poorly correlated
N/A
COGT - ZIVO
20%
Poorly correlated
+2.34%
CLSD - ZIVO
20%
Poorly correlated
-1.13%
More